2012
DOI: 10.5312/wjo.v3.i12.223
|View full text |Cite
|
Sign up to set email alerts
|

Male osteoporosis: A review

Abstract: Osteoporosis in men is a heterogeneous disease that has received little attention. However, one third of worldwide hip fractures occur in the male population. This problem is more prevalent in people over 70 years of age. The etiology can be idiopathic or secondary to hypogonadism, vitamin D deficiency and inadequate calcium intake, hormonal treatments for prostate cancer, use of toxic and every disease or drug use that alters bone metabolism. Risk factors such as a previous history of fragility fracture shoul… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
24
0
5

Year Published

2015
2015
2021
2021

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 38 publications
(29 citation statements)
references
References 130 publications
(153 reference statements)
0
24
0
5
Order By: Relevance
“…There was a significant difference in Group III in respect of age. A significant decrease in BMD in that age group is not expected [17]. Nevertheless, multivariate analysis with logistic regression was applied and the age did not significantly affect the BMD.…”
Section: Discussionmentioning
confidence: 92%
“…There was a significant difference in Group III in respect of age. A significant decrease in BMD in that age group is not expected [17]. Nevertheless, multivariate analysis with logistic regression was applied and the age did not significantly affect the BMD.…”
Section: Discussionmentioning
confidence: 92%
“…In aging men reduced calcium absorption in the intestine results in lower serum concentration of ionized calcium. This leads to an increase in the production of parathyroid hormone (PTH), which stimulates osteoclasts (Herrera et al 2012). It is believed that the reduced testosterone levels may contribute to dysregulation of intracellular Ca 2?…”
Section: Introductionmentioning
confidence: 99%
“…Denosumab tiene también indicación en el tratamiento de la pérdida ósea asociada a la supresión hormonal en hombres con cáncer de próstata con elevado riesgo de fractura. La terapia con testosterona no se recomienda como tratamiento estándar por sus efectos secundarios asociados 132 .…”
Section: Concepto De Fallo En El Tratamientounclassified